IGF1 and hepatocellular carcinoma: Hep3B, PLC/PRF/5 and HepG2 human HCC cell lines were treated in log phase growth in culture dishes with Regorafenib 1–5 μM or IGF1 40 ng/ml alone or in combination with appropriate controls and proliferation was evaluated by MTT assay.